Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CCR5 | P51681 | 12/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13797803 | 0.86 | GPR119 (0.57) | GPR119CCR5 | |
| SCHEMBL14446775 | 0.85 | CCR5 (0.60) | GPR119CCR5 | |
| SCHEMBL6091638 | 0.82 | CCR5 (0.65) | CCR5 | |
| SCHEMBL6091632 | 0.82 | CCR5 (0.65) | CCR5 | |
| SCHEMBL4978196 | 0.79 | GPR119 (0.52) | GPR119 | |
| SCHEMBL6645701 | 0.77 | CCR5 (0.62) | GPR119KCNH2CCR5 | |
| SCHEMBL6673386 | 0.77 | CCR5 (0.57) | GPR119KCNH2CCR5 | |
| SCHEMBL1576264 | 0.77 | GPR119 (0.71) | GPR119 | |
| SCHEMBL2768189 | 0.77 | KCNH2 (0.80) | GPR119KCNH2CCR5 | |
| SCHEMBL2769377 | 0.77 | KCNH2 (0.61) | GPR119KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547789-B2 | Process for the preparation of N-(4-piperidinyl)-N-ethyl-phenylacetamides from N-Boc-4-oxopiperidine | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| US-20080214824-A1 | Process for the Preparation of N-(4-Piperidinyl)-N-Ethyl-Phenylacetamides from N-Boc-4-Oxopiperidine | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1828128-A1 | PROCESS FOR THE PREPARATION OF N-(4-PIPERIDINYL)-N-ETHYL-PHENYLACETAMIDES FROM N-BOC-4-OXOPIPERIDINE | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| WO-2006064221-A1 | PROCESS FOR THE PREPARATION OF N- (4-PIPERIDINYL) -N-ETHYL-PHENYLACETAMIDES FROM N-BOC-4-OXOPIPERIDINE | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1448548-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042205-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | CCR5, CCR2, CCL5 | GPR119 165/4885KCNH2 2988/4885CCR5 1/4885 |
| US-20080214824-A1 | Process for the Preparation of N-(4-Piperidinyl)-N-Ethyl-Phenylacetamides from N-Boc-4-Oxopiperidine | NISCH, NPPA, AZI2 | GPR119 3530/4885KCNH2 139/4885CCR5 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.